GRAIL (NASDAQ:GRAL) Price Target Raised to $118.00

GRAIL (NASDAQ:GRAL) had its price target lifted by Robert W. Baird from $96.00 to $118.00 in a research report report published on Tuesday morning, Marketbeat.com reports. The brokerage currently has an outperform rating on the stock.

GRAL has been the topic of several other research reports. Wolfe Research started coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. UBS Group set a $84.00 price objective on shares of GRAIL in a research report on Thursday, September 17th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Finally, Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and an average target price of $75.10.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $125.21 on Tuesday. The business’s 50-day simple moving average is $77.33 and its 200 day simple moving average is $65.25. The company has a market cap of $5.59 billion, a P/E ratio of -12.84 and a beta of 3.25. GRAIL has a one year low of $41.50 and a one year high of $126.81.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. Analysts predict that GRAIL will post -10.41 earnings per share for the current year.

Insider Activity

In other news, CEO Joshua Ofman sold 61,452 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares of the company’s stock, valued at approximately $35,408,367.54. The trade was a 14.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 4,100 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the completion of the sale, the chief financial officer owned 248,983 shares in the company, valued at approximately $23,240,073.22. This trade represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 78,452 shares of company stock valued at $7,485,691 in the last three months. Insiders own 1.83% of the company’s stock.

Institutional Trading of GRAIL

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its position in shares of GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after acquiring an additional 608,539 shares in the last quarter. State Street Corp lifted its stake in GRAIL by 26.1% during the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after purchasing an additional 493,621 shares during the last quarter. Primecap Management Co. CA bought a new position in GRAIL during the second quarter worth $148,836,000. Baker BROS. Advisors LP boosted its holdings in GRAIL by 27.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after purchasing an additional 455,208 shares during the period. Finally, Bank of America Corp DE boosted its holdings in GRAIL by 29.0% in the first quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after purchasing an additional 205,611 shares during the period.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly supported the evidence for its effectiveness. The vote represents important regulatory progress for GRAIL and its primary commercial product. FDA advisers back safety of Grail’s cancer test, narrowly endorses efficacy
• Positive Sentiment: The recommendation moves Galleri closer to final FDA review. Approval could significantly expand GRAIL’s addressable market, strengthen confidence in its technology and support additional adoption of the prescription test. Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote
• Positive Sentiment: GRAIL also reported PATHFINDER 2 study findings, providing additional clinical data as investors evaluate Galleri’s effectiveness and commercial potential ahead of the FDA decision. GRAIL Reports PATHFINDER 2 Study Findings
• Positive Sentiment: Robert W. Baird raised its price target to $118 from $96 and maintained an “outperform” rating, reflecting greater optimism about Galleri’s regulatory outlook.
• Neutral Sentiment: Trading was temporarily halted ahead of the FDA meeting because of pending news, underscoring the event’s significance and contributing to unusually high volatility. Grail Trading Halted Ahead of FDA AdCom Meeting
• Neutral Sentiment: A report lists short interest at zero shares, implying no measurable short-selling pressure; however, the figure may reflect a reporting anomaly and should be interpreted cautiously.
• Negative Sentiment: The committee’s support for efficacy was narrow, leaving meaningful regulatory uncertainty before the FDA issues its final decision. Goldman Sachs has a “hold” rating, signaling caution after the rally. GRAIL Gets a Hold from Goldman Sachs
• Negative Sentiment: CEO Joshua Ofman and CFO Aaron Freidin sold shares under pre-arranged Rule 10b5-1 plans. The transactions were scheduled and leave both executives with substantial holdings, but may still weigh modestly on sentiment.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.